Novartis data at ESC Congress 2026 reinforce cardiovascular
Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goalsNew AZALEA-TIMI 71…
FDA approves Pluvicto for PSMA+ metastatic
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc](https://www.europesays.com/ch/wp-content/uploads/2026/07/1785239847_https2F2Fmedia.zenfs_.com2Fen2Fglobenewswire.com2F84b0110bbf60eb8397db0461bc3549c4-380x220.jpeg)
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Key figures CHF millions % change January–June 2026 2025 At CER1 In CHF In USD Group sales 30,364…
Novartis delivered sales growth in Q2 and further advanced
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc1, +3% USD), with…
Novartis delivered sales growth in Q2 and further advanced
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc1, +3% USD), with…
Novartis Fabhalta® (iptacopan) receives FDA traditional
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of…
Huntington’s Disease Therapeutics Market Is Going to Boom |
Huntington’s Disease Therapeutics Market The latest study, titled Huntington’s Disease Therapeutics Market 2026, published by Coherent Market Insights,…
AI in Oncology Market to Reach $9.1 Billion by 2035
The global AI in oncology market, valued at USD 1.7 billion in 2024, is on track to reach…
Novartis agrees to acquire a pan-mutant-selective PI3Kα
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…
Chubb Law Accident & Injury Attorneys Donates $1,240 to Birthday
Image: https://www.globalnewslines.com/uploads/2026/06/1781898909.jpg Daytona Beach, FL – Chubb Law Accident & Injury Attorneys [https://chubbfirm.com/] announced a $1,240 donation to…
Novartis Cosentyx® PMR data in New England Journal of
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent…
Companion Diagnostics Market to Reach USD 3.6 Bn by 2036 as Roche,
Companion Diagnostics Market The global companion diagnostics market size was valued at USD 1.2 Bn in 2025 and…